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Acute kidney injury remains a global challenge and, despite the availability of dialysis and 
transplantation, can be fatal. Those that survive an acute kidney injury are at increased risk of 
developing chronic kidney disease and end stage renal failure. Understanding the fundamental 
mechanisms underpinning the pathophysiology of acute kidney injury is critical for developing 
novel strategies for diagnosis and treatment. A growing body of evidence indicates that amplifying 
type 2 immunity may have therapeutic potential in kidney injury and disease. Of particular interest 
are the recently described subset of innate immune cells, termed group 2 innate lymphoid cells. 
Group 2 innate lymphoid cells are crucial tissue-resident immune cells that maintain homeostasis 
and regulate tissue repair at multiple organ sites, including the kidney. They are critical mediators 
of type 2 immune responses following infection and injury. The existing literature suggests that 
activation of group 2 innate lymphoid cells and production of a local type 2 immune milieu is 
protective against renal injury and associated pathology. In this review, we describe the emerging 
role for group 2 innate lymphoid cells in renal homeostasis and repair. We provide an in-depth 
discussion of the most recent literature that use pre-clinical models of acute kidney injury and 
assess the therapeutic effect of modulating group 2 innate lymphoid cell function. We debate the 
potential for targeting these cells as novel cellular therapies in acute kidney injury and discuss the 
implications for future studies and translation. 
 
Keywords 
Group 2 innate lymphoid cells, ILC2, type 2 immunity, innate immunity, alternatively activated 
macrophages, acute kidney injury, ischemia-reperfusion injury.  










Acute kidney injury (AKI), an abrupt decline in kidney function, is a common disorder with 
profound effects on mortality and morbidity [1]. Approximately 13 million people in the US are 
affected by AKI each year and approximately 2 million cases are fatal [2]. Meta-analysis of 
epidemiological studies demonstrated that the pooled incidence of AKI in hospital patients is 22% 
and AKI is independently associated with an up to 16-fold increase in the risk of death [3–5]. 
Indeed, the overall mortality of patients with AKI requiring renal replacement therapy was 46% [4]. 
Acute and chronic kidney disease are strongly interrelated, with patients recovering from AKI at 
increased risk of chronic kidney disease (CKD), and individuals with CKD have a substantially 
increased risk of AKI [6].  
 
AKI can arise from a diverse array of pathophysiologic processes including hemodynamic 
compromise, nephrotoxic injury, autoimmune glomerulonephritis and urine outflow obstruction [7]. 
A common cause of AKI, however, is kidney ischemia, which induces hypoxic cell death in the 
most metabolically active components of the kidney, the tubular epithelium [8] (reviewed in [9]). 
Tubular epithelial injury results in necrosis and shedding of epithelia from the basement membrane, 
a process recognised as histopathological lesions termed acute tubular necrosis (ATN) [9–11]. 
Occlusion of tubular space by necrotic epithelial tissue results in glomerular injury and 
obsolescence [12]. The subsequent reduction in the quantity of functional nephrons (comprising 
afferent and efferent arteriole, glomerulus, tubule and collecting duct) leads to reduced glomerular 
blood flow and filtration, retention of waste products and impaired homeostasis of major 
electrolytes in the systemic circulation [11–13]. 
 
The Kidney Disease Improving Global Outcomes (KDIGO) initiative proposed the definition of 
AKI as an elevation in serum creatinine (SCr) within the prior 7 days, or by a reduction in urine 
output sustained over 6 hours [14]. However, with the recognition that increasing severity of AKI is 
associated with elevated risks of CKD and mortality, the Risk, Injury, Failure, Loss, End stage 










(RIFLE) criteria were proposed to identify and grade injury based on the magnitude of SCr rise and 
urine output reduction [15]. When renal function is impaired for ≥3 months the patient may be 
defined as having CKD [16]. Therefore, a therapeutic window for reducing CKD exists by 
preventing AKI in high risk patients and improving regeneration or repair of the kidney following 
AKI. Importantly, the available therapies for AKI are of a supportive nature and do not treat the 
injury itself [1,17,18]. Hence, there is a clear need for an improved understanding of the cellular 
mechanisms that underpin the pathogenesis of AKI and CKD. 
 
A brief overview of murine experimental models used to study AKI 
Rodents, especially mice, are routinely used to model kidney injury and assess the cellular 
mechanisms due to ease of genetic manipulation and husbandry [19,20]. Male mice are primarily 
used as they display increased susceptibility to renal ischemia [21]. Renal ischemia-reperfusion 
injury (IRI) models are useful since ischemic injuries are common in renal transplantation [22]. 
Ischemia can be induced either in one (unilateral IRI) or both (bilateral IRI) kidneys under 
normothermic or hypothermic conditions [23–25]. Chemical-induced models of injury are also 
used, including adriamycin (doxorubicin) and cisplatin-induced nephropathy [26,27]. Both are well-
documented to cause injury, inflammation and the development of fibrosis and glomerulosclerosis 
[26,27]. However, these compounds are administered systemically and therefore may have off-
target effects on other organs independent of the renal injury. Though there are limitations in each 
experimental model, they have been indispensable for understanding immune responses and 
mechanisms of repair following AKI [19]. Indeed, models such as these have been used to begin to 
explore the functional role of a recently described subset of immune cells called innate lymphoid 
cells (ILCs). 
 
Innate lymphoid cells 










ILCs are categorized into three subsets based on their cytokine profiles and expression of specific 
transcription factors [28]. Group 1 ILCs (ILC1s) include the natural killer (NK) cell lineage and the 
non-NK ILC1s that resemble T helper (TH)1 cells as they require the transcription factor T box 21 
(Tbx21; T-BET) for their development and predominantly produce interferon (IFN)-γ [29]. Group 2 
ILCs (ILC2s) resemble TH2 cells as they require GATA binding protein 3 (GATA3) and produce 
type 2 cytokines, such as interleukin (IL)-4, IL-5, IL-9 and IL-13 [30,31]. Group 3 ILCs (ILC3s) 
comprise subsets that resemble TH17 and TH22 cells and require RAR-related orphan receptor 
gamma (Rorc; RORγT) and produce IL-17 and IL-22 [32,33]. 
 
Natural and inflammatory ILC2s 
ILC2s are rare immune cells but are potent innate producers of type 2 cytokines in response to 
epithelial-derived alarmins, particularly IL-25, IL-33 and thymic stromal lymphopoietin (TSLP) 
[30,31] (Figure 1). ILC2s are also required for the development of effective TH2-mediated adaptive 
immune responses [34]. ILC2s have been suggested to exist in distinct states depending on the 
cytokines which drive their activation [35]. Under homeostatic conditions, natural ILC2s (nILC2s) 
are resident in most tissues, including the kidney, and respond primarily to IL-33 [36]. Indeed, 
nILC2s are defined as being IL-33 receptor (Il1rl1; ST2) positive [31]. Inflammatory ILC2s 
(iILC2s) however, are difficult to detect under homeostatic conditions but are rapidly induced in 
response to IL-25 [37]. The iILC2s represent a subpopulation of ILC2s that are ST2 negative [37]. 
There is evidence of plasticity between ILC states and it has been proposed that iILC2s can act as 
progenitors for nILC2s or even ILC3s [37,38]. These findings indicate that the tissue resident pool 
of nILC2s may be replenished by iILC2s and that resident cells may change in response to certain 
insults. 
 
ILC2s coordinate innate and adaptive immune responses 










ILC2s are resident in murine and human kidneys and exhibit similar type 2 effector cytokine 
profiles [39,40]. IL-4 is produced by ILC2s in response to alarmins from epithelia, helminth 
infection or activation of pattern recognition receptors [41,42]. Interestingly, ILC2s express the IL-4 
receptor and are sensitive to IL-4 through positive feedback, which can further enhance ILC2 
activation and cytokine production [43]. IL-5 is constitutively produced by ILC2s in adult 
mammals, which is required to maintain homeostasis of eosinophils and in turn maintain 
homeostasis of macrophages [36,39]. ILC2s also produce significant amounts of IL-13 which is 
required for recruitment of eosinophils [34,39]. Additionally, IL-13 induces production of mucins 
that are required for tissue homeostasis [44–47]. IL-4 and IL-13 are also critical for the polarization 
of macrophages towards the alternatively activated state (AAM; also known as M2) which can 
dampen excessive inflammatory immune responses and aid with epithelial recovery following 
insults within the kidney and other organs [48] (reviewed in [49]). 
 
ILC2s express the inducible T-cell co-stimulator (ICOS) in addition to its ligand (ICOSL; ICOSLG 
in human) and ICOS-ICOSL interactions between ILC2-ILC2, or between ILC2s and TH 
lymphocytes, enhances cytokine production [50–52] (Figure 1). However, ICOS-ICOSL 
interactions between ILC2s and induced regulatory T cells (iTreg) has the opposite effect [53] 
(Figure 1). ILC2s have also been demonstrated to induce the expansion of TH2 and Treg via the 
expression of the costimulatory molecule TNF superfamily member 4 (Tnfsf4; OX40L) [54]. 
Through the production of IL-13, ILC2s can increase the activation of TH2 cells indirectly through 
dendritic cells that produce the T-cell attracting chemokine CCL17 [34,55]. Additionally, IL-13 can 
recruit macrophages and other phagocytes to the area and cause dendritic cells to migrate to lymph 
nodes and prime naïve T-cells to differentiate into TH2 cells [56,57]. The interaction between ILC2s 
and T cell subsets is complex and tightly regulated to allow heterogeneous function in different 
contexts and locations. 
 










Diversity of ILC2s 
In addition to cytokines, ILC2s also produce the growth factor amphiregulin (AREG), which 
promotes tissue repair [58,59]. In the lung, AREG is essential for resolution of tissue homeostasis 
following viral respiratory infection [60]. Excessive AREG signaling can drive fibrosis in tissues 
such as the lung and kidney, and AREG inhibition may be beneficial in this context [61,62]. Recent 
literature suggests that AREG is also produced by kidney ILC2s and is renoprotective [63]. ILC2s 
have also been shown to express the antigen presenting molecule major histocompatibility complex 
class II (MHCII) [56,57]. This allows them to act as antigen presenting cells (APCs) to stimulate the 
adaptive immune system [56,57]. Recent advances have shown that ILC2s can be neuronally 
regulated, specifically by the neuropeptide neuromedin U (NMU), which signals through the 
surface NMU receptor 1 (NMUR1) to drive their activation and expansion [64–66] (Figure 1). 
 
There is also a growing body of evidence suggesting ILC2s exhibit sexual dimorphism. Depending 
on the tissue, ILC2s express androgen and estrogen receptors and this signaling can alter their 
activity [67–71] (Figure 1). Androgens suppress lung ILC2s and appear to inhibit differentiation of 
ILC2 progenitors from the bone marrow, whereas estrogen has the opposite effect on uterine ILC2s 
[67–71]. Interestingly, multiple reports have found that male mice have fewer tissue resident ILC2s 
within multiple organs, though it is not yet known whether this is the case in humans [67,69,71]. 
Male mice are also more susceptible to kidney injury [21,72]. It is currently unknown whether this 
discrepancy in the number of ILC2s under homeostatic conditions in males is causal or merely 
coincidental. Immune-related factors and signalling pathways such as IFN-γ, IL-27 and signal 
transducer and activator of transcription (STAT)-1 can also suppress the activity of ILC2s [73–75] 
(Figure 1). This may be a mechanism of how pathogens can suppress host repair responses. These 
immune-related factors may also prove to be avenues for modulating ILC2s, either to increase or 
decrease their activity depending on the disease context (Figure 1); similar to that described for type 
2-mediated allergic diseases [76]. 











ILC2s as a potential cellular therapy in renal injury 
ILC2s have recently been shown to have protective effects in mouse models of IRI [77]. 
Administration of recombinant mouse IL-25 prior to IRI induction resulted in the expansion and 
activation of ILC2s, which reduced tubular damage, blood urea nitrogen (BUN) and SCr following 
IRI [77]. To further confirm the role of ILC2s in AKI, ILC2s were isolated from naïve mice and 
stimulated ex vivo with IL-25 [77]. These activated iILC2s were then adoptively transferred into 
recipient mice one day prior to the induction of IRI [77]. Mice that received iILC2s had 
significantly reduced tubular damage, BUN and SCr [77]. Additionally, in vivo IL-25-stimulated 
ILC2s were able to induce an AAM phenotype when co-cultured with kidney resident or bone-
marrow derived macrophages ex vivo [77]. This suggests that ILC2s may induce protective effects 
via the induction of AAMs. However, it is difficult to conclude whether ILC2s are constitutively 
renoprotective without introduction of exogenous IL-25 [77]. Furthermore, iILC2s are 
predominantly responsive to IL-25 and are not considered to be the resident population of ILC2s 
within peripheral tissues [37]. 
 
Following this initial study, the role of ILC2s were investigated in a model of doxorubicin-induced 
nephropathy [78]. A similar approach was used to activate ILC2s in this model, however, the 
cytokine IL-33 was administered for 5 days, starting the day after doxorubicin administration [78]. 
IL-33 induced partial protection against the typical features of doxorubicin-induced nephropathy 
such as tubular inflammation and fibrotic-like remodeling [78]. It was demonstrated that these 
effects occur independently of adaptive immunity using mice deficient in T and B cells (Rag2
-/-
), 




) [78]. However, it is also possible that non-
ILC, ST2 expressing cells such as basophils, eosinophils and mast cells may have important roles in 
protection against renal insult [79–83]. As the ILC-deficient animals lacked T and B cells in 
addition to all ILC subsets, not just ILC2s, it is difficult to conclude that ILC2s are required [78]. In 










this study, IL-33-activated ILC2s were also able to induce an AAM phenotype, which is consistent 
with the mechanism of protection following IL-25 administration [77,78]. Importantly, ILC2s have 
been found in human kidney biopsies, which identifies the potential for these cells to be targeted in 
humans [78]. However, alterations in ILC2 number, function and phenotype in human kidney 
diseases requires further investigation. 
 
The potential complementary effects of IL-2 and IL-33 were investigated using models of chemical-
induced injury, by doxorubicin and cisplatin, in addition to IRI [84]. In each model, treatment with 
IL-2 and IL-33, prior to the induction of injury, protected against injury through the induction of 
both Treg and ILC2s [84]. In addition, a novel hybrid cytokine created from IL-2 and IL-33 (IL233) 
conferred improved protection against injury compared to either cytokine alone [84]. In some 
experiments, IL233 was sufficient to prevent animals from becoming moribund following IRI, 
while all vehicle treated mice were culled within 3-4 days following injury as a humane 
intervention [84]. These results are exciting proof-of-principal evidence for prophylactic treatment 
and intermediate intervention, although it is unlikely this particular therapy will be a viable option 
in humans. The main challenges are that IL-33 has multiple targets and cannot currently be 
administered directly to the kidney without the use of invasive techniques. For patients with type 2-
mediated allergic diseases, such as asthma, systemic activation of ILC2s and other IL-33 responsive 
cells would likely be detrimental and potentially life-threatening. 
 
Most recently, the therapeutic potential of ILC2s in IRI has been further elucidated [63]. IL-33 
treatment or transfer of IL-33-stimulated ILC2s was sufficient to significantly reduce SCr, tubular 
injury and increase survival to 100% out to 28 days post injury [63]. In other studies, treatment with 
murine IL-33, or recombinant human IL-33 in humanized mice, prior to injury, induced similar 
protective effects, although only the day following injury was assessed [63]. Loss of function 
studies were also performed by depletion of ILC2s in T/B cell-deficient (Rag1
-/-
) mice by treatment 










with anti-CD90 [63]. These studies demonstrated that the protective effects of IL-33 were 
significantly diminished in the absence of ILC2s [63]. However, these mice were also depleted of 
other CD90 expressing cells including Treg cells, which may also be critical for this renoprotection 
[63,83,85]. Furthermore, a complex bidirectional relationship exists between ILC2s and Treg 
[63,83,85]. This concept is supported by studies examining the IL233 hybrid cytokine [84]. 
Interestingly, depletion of ILC2s and other CD90 expressing cells did not worsen the severity of 
injury [63].  
 
Our understanding of the innate immune system and its role in the resolution and repair of tissue 
injury is increasing. However, it is far from complete and further characterization of the 
immunological interactions, particularly in kidney disease, is required for translation into clinical 
practice. Recent studies provide a strong rationale to further explore the role of ILC2s in AKI. 
Whilst these provide substantial steps forward in our understanding of the immunology of AKI, it is 
also important to consider that in vivo or ex vivo stimulated cells may establish an artificial state that 
is not representative of their normal functions in human AKI patients. Collectively, these studies 
show that artificially increasing ILC2s provides protection from AKI and decreases pathology 








 mice are deficient in T and B lymphocytes, the 
next important step to is show that the effects are maintained by selective depletion of ILC2s whilst 
preserving the adaptive populations; an approach described by Oliphant and colleagues [56]. This is 
particularly important as a recent report suggests ILCs may be redundant, since there was no 
susceptibility to any particular human disease in patients with ILC lymphopenia [86]. There are also 
conflicting reports which suggest that therapeutic use of IL-33 may be detrimental in AKI, 
discussed below. 
 
Therapeutic potential of IL-33-induced ILC2 activation; a double-edged sword 










Using a cisplatin model, IL-33 treatment was detrimental and led to increased SCr and 
histopathology [87]. Administration of a soluble form of the IL-33 receptor, ST2, significantly 
reduced these features [87]. Consistent results were achieved using IL-33 and soluble ST2 within an 
IRI model, and a similar conclusion was reached using unilateral ureter obstruction [88,89]. Mice 




) were partially protected against the remodeling 
and fibrotic changes following injury, and Il33
-/-
 mice were also protected against features of injury 
following IRI [89,90]. 
 
The dosage of IL-33, length of administration and/or the type of renal injury may drastically alter 
the response exhibited to be advantageous or deleterious. IL-33 treatment was beneficial at a dose 
of 0.3µg per day for 5 days, but was detrimental at a lower dose of 0.05µg per day for 14 days 
[63,88]. Whilst both studies utilized models of IRI, there were differences in the ischemia 
timeframe and in the surgery itself [63,88]. These contrasting conclusions could potentially be 
explained by the composition of the immune cells within the kidney and circulation at the time of 
IL-33 treatment. It is emerging that diverse microbiomes in experimental animals in different 
facilities has substantial impact on immune responses in multiple contexts. One way around this 




Amplification of ILC2s using IL-33 may be effective in attenuating the deleterious consequences of 
AKI in preclinical models. However, since IL-33 may be both beneficial and detrimental, more 
selective strategies are required to target ILC2s to delineate their role in kidney injury and disease. 
The crucial next step is to investigate whether these strategies are sufficient to prevent or delay 
progression to chronic disease and end stage renal failure. It is also plausible that ILC2-activating 
therapies could be detrimental if assessed at later time points due to the exacerbation of fibrosis as a 










result of uncontrolled AAM activation. If indeed ILC2-activating therapies are proven to be 
effective in the prevention of chronic disease, there is still the issue of targeting therapeutics directly 
to ILC2s and only within the kidney. We envision that future therapeutic strategies could involve 
isolating circulating immune cells, such as ILC2s, from patients followed by ex vivo stimulation to 
promote activation and translocation to the kidney, and finally re-introduction to the patient. 
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Figure 1. Factors that regulate ILC2 function. Crucial factors and associated receptors that 
modulate group 2 innate lymphoid cells (ILC2s) to activate (green) or inhibit (red) their survival, 
proliferation and cytokine production. For acute kidney injury, increasing the activity of 
neuromedin U (NMU), IL-25, IL-33 and thymic stromal lymphopoietin (TSLP), and decreasing the 
activity of androgens, IL-27 and interferon-γ (IFN-γ) may be advantageous. Inducible T-cell 
costimulator (ICOS), however, can be excitatory for ILC2-ILC2 interactions, or inhibitory for 
induced regulatory T-lymphocyte (iTreg)-ILC2 interactions depending on co-stimulatory factors 
from the host cell. 
  












Table 1: Methods of in vivo group 2 innate lymphoid cell expansion in experimental AKI 
Method of ILC2 expansion Timing Model Endpoint Reference 
0.3μg rmIL-25, for 5 days OR 2x10
5
 
ILC2s (ex vivo rmIL-25 stim), once 
Prophylactic 30min, bilateral IRI Day 1 [77] 
0.4μg rmIL-33, for 5 days Therapeutic 12mg/kg doxorubicin, i.v Day 14 [78] 
66pmol rmIL-2 & rmIL-33 OR 
66pmol IL233, each for 5 days 
Both 24/26min, bilateral IRI; 
20mg/kg cisplatin, i.p; 




0.3μg rmIL-33, for 5 days OR 1x10
6
 
ILC2s (ex vivo rmIL-33 stim), once 




Day 1/28 [63] 
Summary of the main experimental approaches for ILC2 expansion in the kidney by administration 
of ILC2-activating recombinant mouse (rm) cytokines or adoptive transfer of purified group 2 
innate lymphoid cells (ILC2s) either before (prophylactic) or after (therapeutic) the induction of 
injury. 8-12 week old, male, wild-type BALB/c or C57BL/6 mice were used in each study unless 
specified. In each study, expanding ILC2s was deemed beneficial. 
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